Unknown PHASE1 INTERVENTIONAL 1-arm NCT05293028

Study of F527 in Patients With Relapsed or Refractory Lymphoma

Phase I Clinical Study of Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of F527 in the Treatment of Patients With Relapsed or Refractory Lymphoma

Sponsor: Shandong New Time Pharmaceutical Co., LTD

Conditions Relapsed/Refractory Lymphoma

Interventions F527

Updated 4 times since 2022 Last updated: Mar 14, 2022 Started: May 20, 2022 Primary completion: Nov 20, 2023 Completion: May 20, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05293028, this PHASE1 trial focuses on Relapsed/Refractory Lymphoma and remains ongoing. Sponsored by Shandong New Time Pharmaceutical Co., LTD, it has been updated 4 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jun 2024 — Jul 2024 [monthly]

Unknown Status PHASE1

Status: Not Yet Recruiting → Unknown Status
Apr 2022 — Jun 2024 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shandong New Time Pharmaceutical Co., LTD

Data source: Shandong New Time Pharmaceutical Co., LTD

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China